What Бензобарбитал Treats: Main Uses and Benefits

Бензобарбитал (Benzobarbital) is generally used for long-term therapy for chronic seizure disorders and epilepsy management. The medication class is relevant for seizure disorders, confirming its purpose in the management of symptoms of increased neurological activity.

The medication is applied in addressing symptom clusters that may become intense or disruptive, including generalized tonic-clonic seizures and partial (focal) seizures. It is commonly applied in clinical settings that involve episodic neurological instability where supportive symptom management is appropriate. It is considered relevant in managing recurrent or episodic manifestations in both adults and children.

“The primary therapeutic benefit contributes to easing the overall symptom load by supporting control over the frequency and intensity of convulsive episodes.”

It provides support that helps ease the overall symptom burden and assists with maintaining functional stability during symptomatic periods, which supports general well-being during symptomatic phases.

Quick Fact: Relief for Recurrent Seizures
This medication is applied to help manage episodic neurological instability, assisting with maintaining functional stability.

Regulatory References

1. NIH StatPearls on Barbiturates

Who can and cannot use Бензобарбитал? — Official Regulatory Information

Benzobarbital (Benzonalum) is an anticonvulsant belonging to the barbiturate class, and its use is strictly regulated based on clinical status and patient history, as documented in regulatory guidelines for this type of medication.

Eligibility Classification	Populations/Conditions
Contraindicated	Patients with a known hypersensitivity to barbiturates or any component of the drug.
	Individuals with severe respiratory insufficiency.
	Individuals with marked hepatic impairment.
	Patients diagnosed with porphyria.
Allowed (Target)	Patients with epilepsy (where its use is reported as effective for treatment).

Special Considerations and Restrictions

Regulatory documentation advises caution for patients who are required to operate heavy machinery or perform tasks that demand high levels of mental alertness, due to the central nervous system depressant properties characteristic of barbiturates.

There are no explicit age-related eligibility rules defined as formal contraindications in available summaries, but use must be considered within the context of the potential effects of barbiturates on developing and elderly populations. Pregnancy and lactation status are not defined as a formal contraindication but are described in regulatory documents as requiring careful consideration due to documented risks, without establishing a formal eligibility status.

The interaction profile for Benzobarbital is based on its status as a prodrug for the active compound, Phenobarbital. The official interaction patterns documented in regulatory labeling primarily involve pharmacokinetic alterations and pharmacodynamic effects.

Pharmacokinetic Alterations

Benzobarbital is officially documented as a potent inducer of hepatic microsomal enzymes, including Cytochrome P450 (CYP) enzymes. This effect accelerates the metabolism of co-administered medicinal products, resulting in reduced plasma exposure and diminished effectiveness of those agents. Official regulatory information specifies that this interaction may reduce the effectiveness of hormonal oral contraceptives and certain oral anticoagulants, and enhance the metabolism of corticosteroids. Conversely, the co-administration of agents such as Valproic Acid or Monoamine Oxidase Inhibitors is documented to increase Phenobarbital serum levels. Absorption may also be reduced by the presence of aluminum-containing antacids.

Pharmacodynamic Effects and Restrictions

A key pharmacodynamic interaction involves additive Central Nervous System (CNS) depression. Co-administration with alcohol or other CNS depressants is formally associated with an increased risk of combined depressant effects. Furthermore, the use of this medicine is strictly contraindicated in patients with a history of manifest or latent Acute Porphyrias, as well as in patients who have marked impairment of liver function.

How Бензобарбитал Works

Бензобарбитал, a barbiturate derivative, operates primarily within the central nervous system (CNS) by modulating inhibitory neurotransmission. Its core action involves the gamma-aminobutyric acid (GABA)-A receptor complex. The drug functions as a positive allosteric modulator, binding to a distinct site on the receptor and thereby enhancing the effect of GABA, the principal inhibitory neurotransmitter.

This binding prolongs the duration of chloride ion channel opening, leading to an increased influx of negatively charged chloride ions into the postsynaptic neuron. This continuous ionic flux results in hyperpolarization of the neuronal membrane, which increases the threshold required to fire an action potential and reduces overall neuronal excitability.

Beyond its primary CNS action, the drug is also a potent inducer of hepatic cytochrome P450 enzymes. This process accelerates the metabolic breakdown of various endogenous and exogenous substances by initiating downstream signaling sequences that regulate enzyme synthesis.

How to Use Бензобарбитал: Official Administration Guidelines

Бензобарбитал is administered as an oral tablet and its usage is structured around a continuous, long-term protocol for managing chronic neurological conditions. The official instructions detail specific requirements for dosage, frequency, and timing relative to meals to ensure proper usage.

Administration Scope

Feature	Official Guideline
Route of Administration	Oral (tablet form)
Timing in Relation to Meals	Must be taken after meals (post-prandially)
Dosing Schedule	Typically administered three times per day

---

Dosing Regimens and Titration

Treatment begins with a low initial dose, which is then gradually increased, a process known as titration, every 2 to 3 days until the optimal maintenance dose is achieved. This strategy is designed to establish stable control over time. For adults, the typical maintenance dose per intake is 100 mg to 200 mg, with a maximum daily dose not to exceed 800 mg (0.8 g).

Population-Specific Administration

The prescribing information outlines specific dose adjustments for children, with the required total daily dose depending on the patient's age and weight. For example, children aged 7–10 years are typically prescribed a total daily dose ranging from 150 mg to 300 mg in divided doses. A procedural constraint states that the 100 mg tablet strength is generally not used for pediatric patients under 7 years of age.

---

Course Duration

Therapy with Бензобарбитал is designated as continuous and long-term, often sustained for a minimum of one to three years, even after clinical symptoms have subsided.

Research evidence / Overview of studies for Бензобарбитал

Evidence for use in Chronic Seizure Disorders

The clinical evidence for Benzobarbital (Бензобарбитал) is rooted in its pharmacological class. The medicine was studied for its use in chronic seizure disorders, which includes conditions characterized by fluctuating or episodic manifestations, such as generalized tonic-clonic and partial seizures. This research is aligning with the medicine’s clinical classification.

The available evidence base consists of older Randomized Controlled Trials (RCTs) and various long-term observational cohort studies. These studies were used in research exploring how symptoms evolved in populations with recurrent convulsive episodes. The research highlights changes measured during the study period related to neurological stability.

The findings from these studies describe patterns observed regarding seizure activity in the studied populations. Given that Benzobarbital is metabolized into the active compound Phenobarbital, the understanding of its profile is often contextualized by the broader, more extensive research available for its active metabolite, aligning with its classification.

---

Study Outcomes and Comparison Frameworks

Studies monitored several key outcomes describing episodic or acute changes related to seizure monitoring. These included tracking the total number of convulsive events, as well as the proportion of participants achieving seizure-free status over specified observation periods. Research has also explored differences in patient-reported outcomes describing perceived discomfort or changes in activity level.

Benzobarbital was evaluated in research that included other treatments or placebo. Comparative research examined patterns in monitored outcomes related to systemic or functional imbalance in patients receiving different treatments. Findings from these comparative studies were often mixed and should be viewed as providing context but not individual predictions, as study results reflect the specific conditions under which they were conducted.

---

Long-term Follow-up and Durability of Effect

Evidence related to the medicine is available from long-term observational settings evaluating daily-life functioning. These studies often tracked patient cohorts for extended periods, sometimes spanning several years. This research explored the question of long-term monitoring for conditions where symptoms may vary in intensity.

However, the long-term effects are not fully established through contemporary, high-quality RCTs. While historical data was observed in long-term settings, the follow-up durations were limited in many of the older controlled trials. Research continues to contribute to understanding symptom patterns over years, but a full characterization of the consistency of monitored outcomes remains an area of ongoing study.

---

Research in Specific Patient Groups (Special Populations)

Benzobarbital was studied for use in both adults and children with epilepsy. Studies were applied in research contexts involving fluctuating or unstable symptoms across these age groups. Research describes patterns related to seizure monitoring in these specific populations.

However, data for certain groups remain insufficient. For instance, there is limited information for long-term outcomes specific to older adults or patients with certain comorbid conditions, as these groups were often excluded or underrepresented in older clinical trials. The findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

---

Key Limitations and Areas of Research Uncertainty

The evidence base for Benzobarbital, like many older medicines, has specific limitations. The evidence quality varies across studies, with many older trials having sample sizes that were modest and methodological limitations that are not consistent with current standards. This means certainty remains low regarding some specific monitored findings.

Comparative evidence is lacking for many of the newest anti-seizure medications, as the bulk of the research precedes their development. Overall, the research highlights what is known—the general study patterns—and what is still uncertain: reviews identify methodological concerns. The need for modern, methodologically rigorous trials is a recognized research gap when considering confirmation of findings across diverse populations and long-term treatment scenarios.

Key Studies & References

1. StatPearls: Barbiturates (Pharmacological and Clinical Context)

Common questions about Бензобарбитал (FAQ)

---

Q: If I miss a dose of Бензобарбитал, what should I do?

Regulatory-approved patient information often suggests taking a missed dose as soon as the patient remembers. However, if the time is already close to the next scheduled dose, it may be recommended to skip the missed dose entirely. Patient guidelines advise against taking a double dose to compensate for the one that was skipped.

---

Q: What is the maximum daily dose for an adult?

The maximum total daily dose for adults is defined in the official regulatory monograph for the parent compound. This essential information, along with typical maintenance doses, is typically detailed in the specific Dosing and Administration section of the product labeling.

---

Q: What are the age restrictions for using the 100 mg tablet?

Official administration guidelines note specific constraints regarding age and tablet strength. Regulatory documents indicate that the higher strength tablet is generally not used for pediatric patients under the age of 7.

---

Q: Can I take this medicine with an alcoholic drink?

Regulatory documents explicitly indicate that combining this medicine with alcohol carries a formal risk of additive central nervous system (CNS) depressant effects. This interaction can lead to severe side effects, such as increased drowsiness or impaired coordination.

---

Q: Are there any dietary restrictions (like specific foods or drinks to avoid) while taking Бензобарбитал?

Official administration guidelines state that the tablet must be taken after meals. Product information also notes that the absorption of the medicine may be decreased if taken concomitantly with aluminum-containing antacids. No other specific food restrictions are listed in the regulatory documents.

---

Q: What is the recommended starting dose (initial dose) for adults?

Official regulatory guidance describes a gradual introduction to the medicine, starting with a low initial dose. This process, known as titration, involves slowly increasing the dose until the optimal maintenance level is established.

---

Q: Is it safe to drive or operate heavy machinery while on this medication?

Regulatory documentation advises caution for patients engaging in tasks that require high levels of mental alertness, such as driving or operating heavy machinery. This caution is due to the potential central nervous system (CNS) depressant effects associated with this class of medication.

---

Q: When will I start feeling the effects of the drug?

Studies on the active metabolite, Phenobarbital, classify it as a long-acting barbiturate. Official pharmacokinetic data indicates that the onset of its action, when taken by mouth, is generally 1 hour or longer, with a typical duration of action noted to be between 10 to 12 hours, though individual response may vary.

---

Q: What should I do if I accidentally take too much (overdose)?

In cases of acute intoxication, regulatory guidance identifies general management as consisting of symptomatic and supportive care. This may involve specific medical procedures and supportive monitoring conducted by healthcare professionals to manage blood pressure and other vital signs.

How to Store and Dispose of Benzobarbital (Phenobarbital)

The official storage and disposal requirements for this medication must be followed to maintain product stability and adhere to controlled substance regulations.

---

Storage Requirements

The tablets must be stored at Controlled Room Temperature, which is between 20 C and 25 C (68 F to 77 F), with protection from light and excessive moisture. The medication must remain in its original container, which should be tightly closed and utilize a child-resistant cap. Keep the product strictly out of the sight and reach of children.

---

Disposal Instructions

Disposal of unused or expired product must follow all applicable federal, state, and local regulations for controlled substances. Government guidelines strongly recommend utilizing an authorized drug take-back program. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance before being placed in a sealed container and discarded in the household trash.